The DOI matches its Crossref record; 137 of the 138 references it cites were found in a registry or an index.
Autosomal dominant polycystic kidney disease
Abstract
Autosomal dominant polycystic kidney disease (ADPKD) is the most common hereditary kidney disease and one of the most common causes of end-stage kidney disease. Multiple clinical manifestations, such as enlarged kidneys filled with growing cysts, hypertension, and multiple extrarenal complications, including liver cysts, intracranial aneurysms, and cardiac valvular disease, show that ADPKD is a systemic disorder. New information derived from clinical research using molecular genetics and advanced imaging techniques has provided enhanced tools for assessing the diagnosis and prognosis for individual patients and their families. Phase 3 randomised, placebo-controlled clinical trials have clarified aspects of disease management and a disease-modifying therapeutic drug is now available for patients with high risk of rapid disease progression. These developments provide a strong basis on which to make clear recommendations about the management of affected patients and families. Implementation of these advances has the potential to delay kidney failure, reduce the symptom burden, lessen the risk of cardiovascular complications, and prolong life.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, many agents that protect against PKD, such as rapamycin and the mTOR-independent agents carbamazepine and minoxidil can also restore autophagy in animal models177-182”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [179]
Citations
Cites
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Grantham, J. J., Higashihara, E., Perrone, R. D., Krasa, H. B., Ouyang, J., & Czerwiec, F. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205511 · Cited by 1,614
Self-citationPKD2 , a Gene for Polycystic Kidney Disease That Encodes an Integral Membrane Protein
Mochizuki, T., Wu, G., Hayashi, T., Xenophontos, S. L., Veldhuisen, B., Saris, J. J., Reynolds, D. M., Cai, Y., Gabow, P. A., Pierides, A., et al. (1996) · Science · doi:10.1126/science.272.5266.1339 · Cited by 1,406
Curatolo, P., Bombardieri, R., & Jozwiak, S. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61279-9 · Cited by 1,088
Hughes, J., Ward, C. J., Peral, B., Aspinwall, R., Clark, K., San Millán, J. L., Gamble, V., & Harris, P. C. (1995) · Nature Genetics · doi:10.1038/ng0695-151 · Cited by 910
Unified Criteria for Ultrasonographic Diagnosis of ADPKD
Pei, Y., Obaji, J., Dupuis, A., Paterson, A. D., Magistroni, R., Dicks, E., Parfrey, P., Cramer, B., Coto, E., Torra, R., et al. (2009) · Journal of the American Society of Nephrology · doi:10.1681/asn.2008050507 · Cited by 762
Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease
Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Perrone, R. D., Koch, G., Ouyang, J., McQuade, R. D., Blais, J. D., Czerwiec, F. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1710030 · Cited by 639
Self-citationComparison of phenotypes of polycystic kidney disease types 1 and 2
Hateboer, N., v Dijk, M. A., Bogdanova, N., Coto, E., Saggar-Malik, A. K., Millan, J. L. S., Torra, R., Breuning, M., & Ravine, D. (1999) · The Lancet · doi:10.1016/s0140-6736(98)03495-3 · Cited by 628
Irazabal, M. V., Rangel, L. J., Bergstralh, E. J., Osborn, S. L., Harmon, A. J., Sundsbak, J. L., Bae, K. T., Chapman, A. B., Grantham, J. J., Mrug, M., et al. (2015) · Journal of the American Society of Nephrology · doi:10.1681/asn.2013101138 · Cited by 625
Chapman, A. B., Devuyst, O., Eckardt, K.-U., Gansevoort, R. T., Harris, T., Horie, S., Kasiske, B. L., Odland, D., Pei, Y., Perrone, R. D., et al. (2015) · Kidney International · doi:10.1038/ki.2015.59 · Cited by 611
Self-citationEverolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
Walz, G., Budde, K., Mannaa, M., Nürnberger, J., Wanner, C., Sommerer, C., Kunzendorf, U., Banas, B., Hörl, W. H., Obermüller, N., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003491 · Cited by 587
Research works printed but not linked: 4
- Cornec-Le Gall, 2016, Determinants of disease variability in ADPKD: insights from a cohort of 1634 PKD1 patients, J Am Soc Nephrol, 27, 766A
- Hogan, 2016, Randomized, placebo controlled double blind clinical trial of the somatostatin analog pasireotide LAR for patients with ADPKD or ADPLD with severe liver involvement, J Am Soc Nephrol, 27, 34A
- Chebib, 2018, A practical guide for treatment of rapidly progressive ADPKD with tolvaptan, J Am Soc Nephrol, 29, 2458, 10.1681/asn.2018060590 · DOI · Paper page
- Hogan, 2010, Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease, J Am Soc Nephrol, 21, 1052, 10.1681/asn.2009121291 · DOI · Paper page
Cited by
Targeting integrin pathways: mechanisms and advances in therapy
Pang, X., He, X., Qiu, Z., Zhang, H., Xie, R., Liu, Z., Gu, Y., Zhao, N., Xiang, Q., & Cui, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01259-6 · Cited by 1,275
Autophagy in kidney homeostasis and disease
Tang, C., Livingston, M. J., Liu, Z., & Dong, Z. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0309-2 · Cited by 496
Elshahat, S., Cockwell, P., Maxwell, A. P., Griffin, M., O’Brien, T., & O’Neill, C. (2020) · PLOS ONE · doi:10.1371/journal.pone.0230512 · Cited by 238
Ketosis Ameliorates Renal Cyst Growth in Polycystic Kidney Disease
Torres, J. A., Kruger, S. L., Broderick, C., Amarlkhagva, T., Agrawal, S., Dodam, J. R., Mrug, M., Lyons, L. A., & Weimbs, T. (2019) · Cell Metabolism · doi:10.1016/j.cmet.2019.09.012 · Cited by 223
Oxidative Stress Markers in Chronic Kidney Disease with Emphasis on Diabetic Nephropathy
Vodošek Hojs, N., Bevc, S., Ekart, R., & Hojs, R. (2020) · Antioxidants · doi:10.3390/antiox9100925 · Cited by 175
Metadata
- Authors
- Cornec-Le Gall, E., Alam, A., & Perrone, R. D.
- Affiliations
- McGill University Health Centre (CA)
- Tufts Medical Center (US)
- Corresponding author
- Perrone, Ronald D
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2019-03
- Volume
- 393
- Issue
- 10174
- Pages
- 919-935
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W3152017609
- Cited by
- 624
- References
- 138
- Citations by year
- 2026: 83 · 2025: 108 · 2024: 86 · 2023: 109 · 2022: 88 · 2021: 76 · 2020: 57 · 2019: 13
- FWCI
- 7.75
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Keywords
- autosomal dominant polycystic kidney disease, hereditary kidney disease, end-stage renal disease, renal cysts, hypertension, liver cysts, intracranial aneurysm, valvular heart disease, molecular genetics, diagnostic imaging, prognosis, disease-modifying therapy, disease progression, cardiovascular complications, clinical management
- MeSH terms
- Adult, Aged, Cysts, Female, Genetic Testing, Humans, Liver Diseases, Magnetic Resonance Imaging, Male, Middle Aged, Mutation, Ultrasonography, Randomized Controlled Trials as Topic, Polycystic Kidney, Autosomal Dominant, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Autosomal dominant polycystic kidney disease. https://app.cochat.ai/papers/10.1016/s0140-6736(18)32782-x
- The paper
- Cornec-Le Gall, E., Alam, A., & Perrone, R. D. (2019). Autosomal dominant polycystic kidney disease. The Lancet. https://doi.org/10.1016/s0140-6736(18)32782-x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.